Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade
Axsome Therapeutics shares hit a new 52-week high in mid-day trading Thursday after TD Cowen raised its price target to $300 from $275 and kept a buy rating. The stock traded up to $260.19 and last at $249.73. Other analysts also adjusted targets. CEO Herriot Tabuteau sold 49,670 shares at $241.01 on June 9.
How this was made
The 30-second read
Why it matters
The immediate trading catalyst is TD Cowen’s same-day target increase to $300 alongside a buy rating, coinciding with AXSM printing a new 52-week high intraday.
Market read
Traders can treat this as an upgrade-driven momentum catalyst for AXSM, but it is not accompanied by new clinical/regulatory or earnings guidance in the text.
What to watch
The article also notes recent insider selling (CEO and director) and that the latest quarter missed EPS consensus, which can cap upside despite the upgrade.
Background
AXSM is a clinical-stage CNS biopharmaceutical company; the article references its prior quarterly results and ongoing analyst coverage.
Ticker impact
TD Cowen raised its AXSM price target from $275 to $300 and reiterated a buy rating as shares hit a new 52-week high.
Bullish bias for the session and into the next few days, with follow-through dependent on whether other analysts’ targets converge upward.
The article ties the intraday 52-week-high move to a specific, same-day analyst target increase; however, it provides no new fundamental datapoint beyond the upgrade.
Market effects
Limited read-across: single-name analyst target change in clinical-stage CNS biopharma; no sector-wide policy or trial result disclosed.
Primarily US small/mid-cap biotech sentiment; no cross-region macro catalyst mentioned.
Low—no international deal/regulatory action or global supply-chain shock described.
Counterpoint
A price-target raise can lag fundamentals; without new trial/approval data, the move may fade if broader biotech sentiment turns.
Key entities
- companyAxsome Therapeutics, Inc.
NASDAQ-listed clinical-stage CNS biopharma whose shares hit a new 52-week high after an analyst upgrade/target hike.
- analyst_firmTD Cowen
Raised AXSM price target from $275 to $300 and maintained a buy rating.
